scholarly journals Prognostic utility of the N terminal prohormone of brain natriuretic peptide and the modified Model for End Stage Liver Disease in patients with end stage heart failure

2018 ◽  
Author(s):  
Wioletta Szczurek ◽  
Bożena Szyguła-Jurkiewicz ◽  
Michał Zakliczyński ◽  
Bogumiła Król ◽  
Mariusz Gąsior ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Disease ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Modified Model ◽  
End Stage Liver Disease ◽  
Prognostic Utility ◽  
End Stage Heart Failure ◽  
End Stage

Diastolic Dysfunction in Patients with End-Stage Liver Disease Is Associated with Development of Heart Failure Early after Liver Transplantation

2011 ◽  
Vol 17 (8) ◽  
pp. S19
Author(s):  
Taylor F. Dowsley ◽  
David B. Bayne ◽  
Alan N. Langnas ◽  
Ioana Dumitru ◽  
John R. Windle ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Transplantation ◽  
Liver Disease ◽  
Diastolic Dysfunction ◽  
End Stage Liver Disease ◽  
End Stage

Abstract 12917: Prognostic Value of the Combination of Model for End-stage Liver Disease Excluding Inr Score and Non-alcoholic Fatty Liver Disease Fibrosis Score in Patients Admitted for Acute Heart Failure

Circulation ◽  
2020 ◽  
Vol 142 (Suppl_3) ◽  
Author(s):  
Masatsugu Kawahira ◽  
Takahisa Yamada ◽  
Tetsuya Watanabe ◽  
Takashi Morita ◽  
Yoshio Furukawa ◽  
...  
Keyword(s):  
Heart Failure ◽  
Liver Disease ◽  
Liver Fibrosis ◽  
Ejection Fraction ◽  
Fatty Liver Disease ◽  
Fibrosis Score ◽  
Alcoholic Fatty Liver ◽  
End Stage Liver Disease ◽  
End Stage ◽  
Alcoholic Fatty Liver Disease

Background: Cardiohepatic interactions have been a focus of attention in heart failure(HF), and the model for end-stage liver disease excluding INR (MELD-XI) has been shown to be useful for prediction of poor outcome in patients (pts) with acute decompensated heart failure (ADHF). Furthermore, it has been reported that liver stiffness predicts adverse prognosis in pts with HF. Liver fibrosis is assessed by non-invasive fibrosis markers such as Fibrosis-4 (FIB4) index, non-alcoholic fatty liver disease fibrosis score (NFS) and aminotransferase to platelet ratio index (APRI). Recently, a new group of HF pts with mid-range ejection fraction (HFmrEF) has been defined, separated from reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). However, there is little information available on the comparison of prognostic significance of MELD-XI and liver fibrosis scores in ADHF pts, relating to LVEF. Methods: We prospectively studied 466 consecutive ADHF pts (HFrEF (LVEF≦40%): n=164, HFmrEF (40<LVEF<50): n=104 and HFpEF (LVEF≧50%): n=198). At the discharge, we calculated MELD-XI, FIB4 index , NFS, and APRI. The endpoint was all cause death (ACD). Results: During a follow-up period of 2.8±1.5 years, 143 pts had ACD. At multivariate Cox analysis, MELD-XI and FIB4 index was independently associated with ACD irrespective of LVEF. The pts with both greater MELD-XI ([HFrEF]≥25.8, [HFmrEF]≥33.2, [HFpEF]≥30.1) and greater FIB4 index ([HFrEF]≥2.58, [HFmrEF]≥2.58, [HFpEF]≥2.22) had a significantly increased risk of ACD than those with either and none of them in all three groups. Conclusions: The combination of MELD-XI and FIB4 index might be useful for stratifying pts at risk for ACD in ADHF pts with irrespective of LVEF.

Sign in / Sign up

Export Citation Format

Share Document